Neuron23 Inc.
Neuron23 is a biotechnology company dedicated to developing precision medicines for genetically defined neurological and immunological diseases. Using advanced data science, human genetics, and AI-enabled drug discovery platforms, the company aims to create targeted therapies for devastating diseases such as Parkinson's, multiple sclerosis, and systemic autoimmune and inflammatory diseases. Founded in 2018 and based in South San Francisco, CA, Neuron23 is committed to transforming treatment approaches through innovation, collaboration, and a patient-centric mission.
Industries
Nr. of Employees
small (1-50)
Neuron23 Inc.
343 Oyster Point Blvd, Suite 120, South San Francisco, CA 94080
Products
NEU-411 (LRRK2 inhibitor)
Oral, brain-penetrant small-molecule inhibitor targeting LRRK2 developed for LRRK2-driven Parkinson’s disease; evaluated in Phase 1 and being studied in a global Phase 2 trial with biomarker and digital endpoints.
NEU-111 (peripherally restricted TYK2 inhibitor)
Oral allosteric TYK2 inhibitor designed to reduce peripheral immune signaling with Phase 1 clinical evaluation for safety, tolerability, and pharmacokinetics.
NEU-627 (central TYK2 inhibitor)
Preclinical highly potent brain-penetrant TYK2 inhibitor advanced for multiple sclerosis and other neuroinflammatory diseases.
NEU-723 (LRRK2 inhibitor; earlier clinical candidate)
Brain-penetrant LRRK2 inhibitor that entered First-in-Human Phase 1 testing; part of the LRRK2 discovery portfolio.
NGS-based companion diagnostic assay (investigational)
Blood-based next-generation sequencing assay and predictive algorithm intended to identify patients with genetic signatures (SNP panel and model) consistent with elevated pathway activity and likely response to LRRK2-targeted therapy.
NEU-411 (LRRK2 inhibitor)
Oral, brain-penetrant small-molecule inhibitor targeting LRRK2 developed for LRRK2-driven Parkinson’s disease; evaluated in Phase 1 and being studied in a global Phase 2 trial with biomarker and digital endpoints.
NEU-111 (peripherally restricted TYK2 inhibitor)
Oral allosteric TYK2 inhibitor designed to reduce peripheral immune signaling with Phase 1 clinical evaluation for safety, tolerability, and pharmacokinetics.
NEU-627 (central TYK2 inhibitor)
Preclinical highly potent brain-penetrant TYK2 inhibitor advanced for multiple sclerosis and other neuroinflammatory diseases.
NEU-723 (LRRK2 inhibitor; earlier clinical candidate)
Brain-penetrant LRRK2 inhibitor that entered First-in-Human Phase 1 testing; part of the LRRK2 discovery portfolio.
NGS-based companion diagnostic assay (investigational)
Blood-based next-generation sequencing assay and predictive algorithm intended to identify patients with genetic signatures (SNP panel and model) consistent with elevated pathway activity and likely response to LRRK2-targeted therapy.
Services
Design and run randomized, double-blind, placebo-controlled clinical studies incorporating biomarker-driven patient selection and digital endpoints.
Co-development and validation of blood-based NGS assays and predictive algorithms to detect genetic signatures that predict therapeutic responsiveness.
Identification and validation of translational biomarkers (including fluid biomarkers and CNS neuroinflammatory markers) and evaluation in preclinical disease models.
Machine-learning approaches that integrate large genomic datasets to prioritize targets and define patient subpopulations for precision therapies.
Design and synthesis of selective small-molecule inhibitors optimized for potency, selectivity, and CNS penetration or peripheral restriction depending on indication.
Design and run randomized, double-blind, placebo-controlled clinical studies incorporating biomarker-driven patient selection and digital endpoints.
Co-development and validation of blood-based NGS assays and predictive algorithms to detect genetic signatures that predict therapeutic responsiveness.
Identification and validation of translational biomarkers (including fluid biomarkers and CNS neuroinflammatory markers) and evaluation in preclinical disease models.
Machine-learning approaches that integrate large genomic datasets to prioritize targets and define patient subpopulations for precision therapies.
Design and synthesis of selective small-molecule inhibitors optimized for potency, selectivity, and CNS penetration or peripheral restriction depending on indication.
Expertise Areas
- Clinical trial management (Phase 1–2)
- Biomarker discovery and translational research
- Precision medicine and patient stratification
- Medicinal chemistry and small-molecule discovery
Key Technologies
- Next-generation sequencing (NGS)
- Machine learning / AI for target discovery and stratification
- Digital biomarkers / smartphone-based monitoring
- Small-molecule kinase inhibition
News & Updates
Neuron23 announced details of its Phase 2 NEULARK clinical trial of NEU-411, a brain-penetrant, potent and selective inhibitor of LRRK2, in early Parkinson’s disease. The trial uses a digital biomarker developed by Roche for enhanced precision and patient stratification.
Neuron23 announced the initiation of dosing in a Phase 1 clinical trial of NEU-111, a potent and highly selective oral TYK2 inhibitor, in healthy volunteers. The trial aims to evaluate safety, tolerability, and pharmacodynamics.
Neuron23 published a manuscript in PNAS exploring the role of TYK2 inhibition in neuroinflammation, microglia, and astrocyte regulation, demonstrating the potential of TYK2 inhibitors for neuroinflammatory diseases.
Neuron23 announced the closing of a $100 million Series C financing round led by SoftBank Vision Fund 2, to accelerate development of its pipeline targeting LRRK2 and TYK2, and to expand its AI and biomarker platforms.
Neuron23 and QIAGEN announced a collaboration to develop a next-generation sequencing companion diagnostic for a novel Parkinson’s disease drug, combining drug discovery with advanced diagnostic development.
Neuron23 announced details of its Phase 2 NEULARK clinical trial of NEU-411, a brain-penetrant, potent and selective inhibitor of LRRK2, in early Parkinson’s disease. The trial uses a digital biomarker developed by Roche for enhanced precision and patient stratification.
Neuron23 announced the initiation of dosing in a Phase 1 clinical trial of NEU-111, a potent and highly selective oral TYK2 inhibitor, in healthy volunteers. The trial aims to evaluate safety, tolerability, and pharmacodynamics.
Neuron23 published a manuscript in PNAS exploring the role of TYK2 inhibition in neuroinflammation, microglia, and astrocyte regulation, demonstrating the potential of TYK2 inhibitors for neuroinflammatory diseases.
Neuron23 announced the closing of a $100 million Series C financing round led by SoftBank Vision Fund 2, to accelerate development of its pipeline targeting LRRK2 and TYK2, and to expand its AI and biomarker platforms.
Neuron23 and QIAGEN announced a collaboration to develop a next-generation sequencing companion diagnostic for a novel Parkinson’s disease drug, combining drug discovery with advanced diagnostic development.